Haemonetics Corp Elects New Director; Shareholders Approve Amended LTIP

What Happened

• Haemonetics Corporation (HAE) filed an 8-K on July 28, 2026 reporting two governance actions. On July 24, 2026 the Board elected Dr. Martin Madaus as a director, effective immediately. Dr. Madaus is Senior Operating Executive at The Carlyle Group and will stand for shareholder election at Haemonetics’ 2027 annual meeting.
• Also on July 24, 2026 shareholders approved an amendment and restatement of the Haemonetics 2019 Long-Term Incentive Compensation Plan. The Amended Plan authorizes 4,680,000 additional shares for issuance, extends the plan term through 2036, and includes technical and conforming updates. The full Amended Plan is filed as Exhibit 10.1 to the 8-K.

Key Details

• Director appointment: Martin Madaus elected July 24, 2026; expected committee assignments — Audit Committee and Governance & Compliance Committee.
• Director compensation: Dr. Madaus will receive the company’s standard non-employee director pay, including an annual equity award with an approximate value of $200,000.
• Amended LTIP: adds 4,680,000 shares to the plan and extends its term through 2036.
• Administrative items: Dr. Madaus will enter the company’s standard indemnification agreement; press release announcing the board appointment is filed as Exhibit 99.1.

Why It Matters

• Board composition: Adding a director with private equity and healthcare operations experience may strengthen oversight and strategic guidance, particularly on finance and governance matters given his expected Audit and Governance Committee roles.
• Compensation program: The shareholder-approved increase in the LTIP share pool and extension through 2036 gives Haemonetics more equity awards to use for executive and employee incentives and retention. That is material for investors because it affects potential future share-based dilution and the company’s ability to grant equity as part of pay packages.
• No financial results or management departures were reported in this filing; the actions are governance and compensation-related items disclosed under Form 8-K.